MediWound Ltd (MDWD) - Financial and Strategic SWOT Analysis Review
MediWound Ltd (MDWD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
MediWound Ltd (MediWound) is a biopharmaceutical company that develops, manufactures and markets novel therapeutics to address the unmet needs in the areas of chronic, severe burns, other hard-to-heal wounds and for connective tissue disorders. The company uses its patented proteolytic enzyme technology for the development of its products. The company offers NexoBrid, a drug for the removal of damaged or dead tissue, namely, eschar, in adults with severe burns (deep partial and full-thickness thermal burns). EscharEX, pipeline drug candidate for the removal of damaged, dead or infected tissues from chronic wounds; MWPC003, a pre-clinical candidate for treating connective tissue Disorders. The company markets NexoBrid in the Europe, Israel through its own commercial organization and in Russia, Peru, India, Bangladesh, South Korea, Argentina through distributors. MediWound is headquartered in Yavne, Israel.
MediWound Ltd Key Recent Developments
Nov 16,2021: MediWound Reports Third Quarter 2021 Financial Results
Aug 10,2021: MediWound Reports Second Quarter Financial Results
May 05,2021: MediWound Reports First Quarter 2021 Financial Results
Apr 26,2021: MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
Feb 25,2021: MediWound reports fourth quarter and full-year 2020 financial results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
MediWound Ltd (MediWound) is a biopharmaceutical company that develops, manufactures and markets novel therapeutics to address the unmet needs in the areas of chronic, severe burns, other hard-to-heal wounds and for connective tissue disorders. The company uses its patented proteolytic enzyme technology for the development of its products. The company offers NexoBrid, a drug for the removal of damaged or dead tissue, namely, eschar, in adults with severe burns (deep partial and full-thickness thermal burns). EscharEX, pipeline drug candidate for the removal of damaged, dead or infected tissues from chronic wounds; MWPC003, a pre-clinical candidate for treating connective tissue Disorders. The company markets NexoBrid in the Europe, Israel through its own commercial organization and in Russia, Peru, India, Bangladesh, South Korea, Argentina through distributors. MediWound is headquartered in Yavne, Israel.
MediWound Ltd Key Recent Developments
Nov 16,2021: MediWound Reports Third Quarter 2021 Financial Results
Aug 10,2021: MediWound Reports Second Quarter Financial Results
May 05,2021: MediWound Reports First Quarter 2021 Financial Results
Apr 26,2021: MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
Feb 25,2021: MediWound reports fourth quarter and full-year 2020 financial results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
MediWound Ltd - Key Facts
MediWound Ltd - Key Employees
MediWound Ltd - Key Employee Biographies
MediWound Ltd - Major Products and Services
MediWound Ltd - History
MediWound Ltd - Company Statement
MediWound Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
MediWound Ltd - Business Description
Geographical Segment: International (excluding the US)
Performance
Geographical Segment: The US
Performance
R&D Overview
MediWound Ltd - SWOT Analysis
SWOT Analysis - Overview
MediWound Ltd - Strengths
MediWound Ltd - Weaknesses
MediWound Ltd - Opportunities
MediWound Ltd - Threats
MediWound Ltd - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
MediWound Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MediWound Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MediWound Ltd, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Nov 16, 2021: MediWound Reports Third Quarter 2021 Financial Results
Aug 10, 2021: MediWound Reports Second Quarter Financial Results
May 05, 2021: MediWound Reports First Quarter 2021 Financial Results
Apr 26, 2021: MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
Feb 25, 2021: MediWound reports fourth quarter and full-year 2020 financial results
Feb 25, 2021: MediWound to Participate in Upcoming March Investment Conferences
Feb 21, 2021: MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Feb 16, 2021: MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021
Jan 05, 2021: MediWound to Participate in Upcoming Investor Conferences in January
Nov 10, 2020: MediWound reports third quarter 2020 financial results
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
MediWound Ltd - Key Facts
MediWound Ltd - Key Employees
MediWound Ltd - Key Employee Biographies
MediWound Ltd - Major Products and Services
MediWound Ltd - History
MediWound Ltd - Company Statement
MediWound Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
MediWound Ltd - Business Description
Geographical Segment: International (excluding the US)
Performance
Geographical Segment: The US
Performance
R&D Overview
MediWound Ltd - SWOT Analysis
SWOT Analysis - Overview
MediWound Ltd - Strengths
MediWound Ltd - Weaknesses
MediWound Ltd - Opportunities
MediWound Ltd - Threats
MediWound Ltd - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
MediWound Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MediWound Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MediWound Ltd, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Nov 16, 2021: MediWound Reports Third Quarter 2021 Financial Results
Aug 10, 2021: MediWound Reports Second Quarter Financial Results
May 05, 2021: MediWound Reports First Quarter 2021 Financial Results
Apr 26, 2021: MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
Feb 25, 2021: MediWound reports fourth quarter and full-year 2020 financial results
Feb 25, 2021: MediWound to Participate in Upcoming March Investment Conferences
Feb 21, 2021: MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Feb 16, 2021: MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021
Jan 05, 2021: MediWound to Participate in Upcoming Investor Conferences in January
Nov 10, 2020: MediWound reports third quarter 2020 financial results
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
MediWound Ltd, Key Facts
MediWound Ltd, Key Employees
MediWound Ltd, Key Employee Biographies
MediWound Ltd, Major Products and Services
MediWound Ltd, History
MediWound Ltd, Subsidiaries
MediWound Ltd, Key Competitors
MediWound Ltd, Ratios based on current share price
MediWound Ltd, Annual Ratios
MediWound Ltd, Annual Ratios (Cont...1)
MediWound Ltd, Annual Ratios (Cont...2)
MediWound Ltd, Interim Ratios
MediWound Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MediWound Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MediWound Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
MediWound Ltd, Key Facts
MediWound Ltd, Key Employees
MediWound Ltd, Key Employee Biographies
MediWound Ltd, Major Products and Services
MediWound Ltd, History
MediWound Ltd, Subsidiaries
MediWound Ltd, Key Competitors
MediWound Ltd, Ratios based on current share price
MediWound Ltd, Annual Ratios
MediWound Ltd, Annual Ratios (Cont...1)
MediWound Ltd, Annual Ratios (Cont...2)
MediWound Ltd, Interim Ratios
MediWound Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MediWound Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MediWound Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
MediWound Ltd, Performance Chart (2016 - 2020)
MediWound Ltd, Ratio Charts
MediWound Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MediWound Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
MediWound Ltd, Performance Chart (2016 - 2020)
MediWound Ltd, Ratio Charts
MediWound Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MediWound Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021